Portal de Periódicos da CAPES

Defects in insulin action in chronic heart failure

2000; Wiley; Volume: 2; Issue: 4 Linguagem: Inglês

10.1046/j.1463-1326.2000.00058.x

1463-1326

Wolfram Doehner, Stefan D. Anker, Andrew J.S. Coats,

Diabetes Treatment and Management

Diabetes, Obesity and MetabolismVolume 2, Issue 4 p. 203-212 Defects in insulin action in chronic heart failure Wolfram Doehner, Wolfram Doehner Department of Cardiac Medicine, National Heart and Lung Institute, London, UKSearch for more papers by this authorStefan D. Anker, Stefan D. Anker Department of Cardiac Medicine, National Heart and Lung Institute, London, UK Franz-Volhard-Klinik (Charité, Campus Berlin Buch), Max-Delbrück Centrum, Berlin, GermanySearch for more papers by this authorAndrew J. S. Coats, Andrew J. S. Coats Department of Cardiac Medicine, National Heart and Lung Institute, London, UKSearch for more papers by this author Wolfram Doehner, Wolfram Doehner Department of Cardiac Medicine, National Heart and Lung Institute, London, UKSearch for more papers by this authorStefan D. Anker, Stefan D. Anker Department of Cardiac Medicine, National Heart and Lung Institute, London, UK Franz-Volhard-Klinik (Charité, Campus Berlin Buch), Max-Delbrück Centrum, Berlin, GermanySearch for more papers by this authorAndrew J. S. Coats, Andrew J. S. Coats Department of Cardiac Medicine, National Heart and Lung Institute, London, UKSearch for more papers by this author First published: 25 December 2001 https://doi.org/10.1046/j.1463-1326.2000.00058.xCitations: 12 Dr Stefan Anker, MD PhD, Department of Cardiac Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6LY, UK. E-mail:[email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Thom, TJ & Epstein, FH. Heart disease, cancer, and stroke mortality trends and their interrelations: an international perspective. Circulation 1994; 90, 574 582. 2 Sans, S, Kesteloot, H, Kromhout, D. The burden of cardiovascular diseases mortality in Europe: Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 1997; 18, 1231 1248. 3 Cleland, JGF. Heart failure: a medical hydra. Lancet 1998; 352 (Suppl.), 1 2. 4 Ho, KK, Anderson, KM, Kannel, WB, Grossman, W, Levy, D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88, 107 115. 5 Wilson, JR, Schwartz, JS, Sutton, MS et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol 1983; 2, 403 410. 6 Brophy, JM, Deslauriers, G, Rouleau, JL. Long-term prognosis of patients presenting to the emergency room with decompensated congestive heart failure. Can J Cardiol 1994; 10, 543 547. 7 Cowie, MR, Mosterd, A, Wood, DA et al. The epidemiology of heart failure. Eur Heart J 1997; 18, 208 225. 8 Kannel, WB, Ho, K, Thom, T. Changing epidemiological features of cardiac failure. Br Heart J 1994; 72 (Suppl.), S3 S9. 9 McGovern, PG, Pankow, JS, Shahar, E et al. Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. N Engl J Med 1996; 334, 884 890. 10 Elkayam, U, Amin, J, Mehra, A, Vasquez, J, Weber, L, Rahimtoola, SH.. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990; 82, 1954 61. 11 Goldstein, RE, Boccuzzi, SJ, Cruess, D, Nattel, S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; Multicenter Diltiazem Postinfarction Research Group. Circulation 1991; 83, 52 60. 12 Packer, M, Carver, JR, Rodeheffer, RJ et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325, 1468 1475. 13 Packer, M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20, 248 254. 14 Swedberg, K, Enroth, P, Kjekshus, J, Wilhelmson, L. for the CONCENSUS II trial study group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82, 1730 1736. 15 Francis, GS, Cohn, JN, Johnson, G, Rector, TS, Goldman, S, Simon, A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-Heft VA Cooperative Studies Group. Circulation 1993; 87 (Suppl.): VI40–VI48. 16 Sigurdsson, A & Swedberg, K. The role of neurohormonal activation in chronic heart failure and postmyocardial infarction. Am Heart J 1996; 132, 229 234. 17 Pool, PE. Neurohormonal activation in the treatment of congestive heart failure: basis for new treatments? Cardiology 1998; 90, 1 7. 18 Mancini, DM, Walter, G, Reichek, N et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992; 85, 1364 1373. 19 Harrington, D, Anker, SD, Chua, TP et al. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J Am Coll Cardiol 1997, 30, 1758 1764. 20 Anker, SD, Ponikowski, PP, Clark, AL et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20, 683 693. 21 Drexler, H. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69, 1596 1601. 22 Hornig, B, Maier, V, Drexler, H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996; 93, 210 214. 23 Wilson, JR, Martin, JL, Schwartz, D, Ferraro, N. Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow of skeletal muscle. Circulation 1984; 69, 1079 1087. 24 Anker, SD, Swan, JW, Volterrani, M et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur Heart J 1997; 18, 259 269. 25 Anker, SD, Volterrani, M, Egerer, KR et al. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure. QJM 1998; 91, 199 203. 26 Anker, SD, Clark, AL, Teixeira, MM, Hellewell, PG, Coats, AJ. Loss of bone mineral in patients with cachexia due to chronic heart failure. Am J Cardiol 1999; 83, 612 615. 27 Anker, SD, Chua, TP, Ponikowski, P et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96, 526 534. 28 Anker, SD & Coats, AJ. Cardiac cachexia: a syndrome with impaired survival and immune and neuroendocrine activation. Chest 1999; 115, 836 847. 29 Coats, AJ, Clark, AL, Piepoli, M, Volterrani, M, Poole-Wilson, PA. Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 1994; 72 (Suppl.), S36 S39. 30 Piepoli, M, Clark, AL, Volterrani, M, Adamopoulos, S, Sleight, P, Coats, AJ. Contribution of muscle afferents to the hemodynamic, autonomic, and ventilatory responses to exercise in patients with chronic heart failure: effects of physical training. Circulation 1996; 93, 940 952. 31 Piepoli, M, Ponikowski, P, Clark, AL, Banasiak, W, Capucci, A, Coats, AJA. neural link to explain the 'muscle hypothesis' of exercise intolerance in chronic heart failure. Am Heart J 1999; 137, 1050 1056. 32 Chua, TP, Ponikowski, P, Webb-Peploe, K et al. Clinical characteristics of chronic heart failure patients with an augmented peripheral chemoreflex. Eur Heart J 1997; 18, 480 486. 33 Ponikowski, P, Chua, TP, Piepoli, M et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 1997; 96, 2586 2594. 34 Beck-Nielsen, H. Insulin resistance: a scientific and clinical challenge. Diabetes Metab Rev 1989; 5, 529 530. 35 Epstein, FH. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 1991; 325, 938 948. 36 Toft, I, Bonaa, KH, Jenssen, T. Insulin resistance in hypertension is associated with body fat rather than blood pressure. Hypertension 1998; 32, 115 122. 37 Lillioja, S. Impaired glucose tolerance in Pima Indians. Diabet Med 1996, 13 (Suppl.), S127 S132. 38 Anderson, EA, Hoffman, RP, Balon, TW, Sinkey, CA, Mark, AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991; 87, 2246 2252. 39 Ferrannini, E, Vichi, S, Beck-Nielsen, H, Laakso, M, Paolisso, G, Smith, U. Insulin action and age: European Group for the Study of Insulin Resistance (EGIR). Diabetes 1996; 45, 947 953. 40 Hotamisligil, GS & Spiegelman, BM. Tumour necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994; 43, 1271 1278. 41 Steinberg, HO, Chaker, H, Laaming, R, Johnson, A, Brechtel, G, Baron, AD. Obesity/insulin resistance is associated with endothelial dysfunction: implication for the syndrome of insulin resistance. J Clin Invest 1996; 97, 2601 2610. 42 Paolisso, G & Giugliano, D. Oxidative stress and insulin action: is there a relationship? Diabetologia 1996; 39, 357 363. 43 Laakso, M, Edelman, SV, Brechtel, G, Baron, AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest 1990; 85, 1844 1852. 44 Feldman, RD & Bierbrier, GS. Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet 1993; 342, 707 709. 45 Baron, AD & Brechtel, G. Insulin differentially regulates systemic and skeletal muscle vascular resistance. Am J Physiol 1993; 265, E61 E67. 46 Steinberg, HO, Brechtel, G, Johnson, A, Fineberg, N, Baron, AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94, 1172 1179. 47 De Caterina, R, Libby, P, Peng, HB et al. Nitric oxide decreases cytokine-induced endothelial activation: nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96, 60 68. 48 Steinberg, HO, Chaker, H, Leaming, R, Johnson, A, Brechtel, G, Baron, AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. Clin Invest 1996; 97, 2601 2610. 49 Cleland, SJ, Petrie, JR, Ueda, S, Elliott, HL, Connell, JM. Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. Hypertension 1999; 33, 554 558. 50 Yang, YJ, Hope, ID, Ader, M, Bergman, RN. Insulin transport across capillaries is rate limiting for insulin action in dogs. J Clin Invest 1989; 84, 1620 1628. 51 Bergmann, RN, Bradley, DC, Adler, M. Advances in Experimental Medicine and Biology. New Concepts in the Pathogenesis of NIDDM. New York. Plenum., 1993: 181 198. 52 Lillioja, S, Young, AA, Culter, CL et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 1987; 80, 415 424. 53 Greene, AS, Tonellato, PJ, Lui, J, Lombard, JH, Cowley, Aw Jr. Microvascular rarefaction and tissue vascular resistance in hypertension. Am J Physiol 1989; 256, H126 H131. 54 Vicaut, E. Hypertension and the microcirculation: a brief overview of experimental studies. J Hypertens 1992; 10 (Suppl.), S59 S68. 55 Volterrani, M, Clark, AL, Ludman, PF et al. Predictors of exercise capacity in chronic heart failure. Eur Heart J 1994; 15, 801 809. 56 Drexler, H, Hayoz, D, Munzel, T et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69, 1596 1601. 57 Ferrari, R, Bachetti, T, Agnoletti, L, Comini, L, Curello, S. Endothelial function and dysfunction in heart failure. Eur Heart J 1998; 19 (Suppl.), G41 G74. 58 Bristow, MR. The adrenergic nervous system in heart failure. N Engl J Med 1984; 311, 850 851. 59 Cohn, JN, Levine, TB, Olivari, MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311, 819 823. 60 Rowe, JN, Young, JB, Minaker, KL, Stevens, AL, Pallotta, J, Landsberg, L. Effect of insulin and glucose infusion on sympathetic nervous system activity in normal man. Diabetes 1981; 30, 219 225. 61 Anderson, EA, Sinkey, CA, Lowton, WJ, Mark, AL. Elevated Sympathetic nerve activity in a borderline hypertensives humans: evidence from direct intraneural recordings. Hypertension 1989; 14, 177 183. 62 Vollenweider, P, Tappy, L, Randin, D et al. Differential effects of hyperinsulinemia and carbohydrate metabolism on sympathetic nerve activity and muscle blood flow in humans. J Clin Invest 1993; 92, 147 154. 63 Stout, RW. Insulin and atheroma 20 year perspective. Diabetes Care 1990; 1, 631 654. 64 Haffner, SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999; 84, 11J 14J. 65 Paolisso, G, De Riu, S, Marrazzo, G, Verza, M, Varricchio, M, D'onofrio, F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991; 40, 972 977. 66 Swan, JW, Walton, C, Godsland, IF, Clark, AL, Coats, AJS, Oliver, MF. Insulin resistance in chronic heart failure. Eur Heart J 1994; 15, 1528 1532. 67 Swan, JW, Anker, SD, Walton, C et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30, 527 532. 68 Marangou, AG, Alford, FP, Word, F et al. Hormonal effect of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism 1988; 37, 886 891. 69 Bergman, RN, Ider, YZ, Bowden, CR, Cobelli, C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236, E667 E677. 70 Swan, JW, Walton, C, Godsland, IF. Assessment of insulin sensitivity in man: a comparison of minimal model- and euglycaemic clamp-derived measures in health and heart failure. Clin Sci Colch 1994; 86, 317 322. 71 Levine, B, Kalman, J, Mayer, L, Fillit, HM, Packer, M. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323, 236 241. 72 Anker, SD, Egerer, KR, Volk, HD, Kox, WJ, Poole-Wilson, PA, Coats, AJ. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol 1997; 79, 1426 1430. 73 Torre-Amione, G, Kapadia, S, Lee, J et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93, 704 711. 74 Hotamisligil, GS, Murray, DL, Chay, LN, Spiegelman, BM. TNF-α inhibits signalling from insulin receptor. Proc Nat Acad Sci 1994; 91, 4854 4858. 75 Hoffman, C, Lorenz, K, Braithwaite, SS, Colca, JR, Polazuk, J, Fokhaus, S. Altered gene expression for tumor necrosis factor-α and its receptor during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134, 264 270. 76 Anker, S, Clark, AL, Kemp, M et al. Tumor necrosis factor-α and steroid metabolism in chronic heart failure: possible relation to muscle wasting. J Am Coll Cardiol 1997; 30, 997 1001. 77 Anker, SD, Ponikowski, P, Varney, S et al. Wasting as independent risk factor of survival in chronic heart failure. Lancet 1997; 349, 1050 1053. 78 Schaufelberger, M, Eriksson, BO, Grimby, G, Held, P, Swedberg, K. Skeletal muscle alterations in patients with chronic heart failure. Eur Heart J 1997; 18, 971 980. 79 Sullivan, MJ, Green, HJ, Cobb, FR. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990; 81, 518 527. 80 Anker, SD, Leyva, F, Godsland, IF, Stevenson, JC, Coats, AJS. Skeletal muscle weakness is related to insulin resistance in patients with chronic heart failure. Circulation 1997; 96 (Suppl.): I−753. 81 Goldner, MG, Zurkowitz, H, Akgren, S. Hyperglycaemia and glucosuria due to thiazide derivates administered in diabetes mellitus. N Engl J Med 1960; 262, 405. 82 Shapiro, AP, Benedek, TG, Small, JL. Effect of thiazides on carbohydrate metabolsim in patients with hypertension. N Engl J Med 1961; 265, 1028 1033. 83 Murphy, MB, Lewis, PJ, Kohner, E, Schumer, B, Dollery, CT. Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up. Lancet 1982; 2, 1293 1295. 84 MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304, 405 412. 85 Amery, A, Birkenhager, W, Brixko, P et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients: a second report from the European Working Party on high blood pressure in the elderly (EWPHE). Postgrad Med J 1986; 62, 919 924. 86 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991; 265, 3255 3264. 87 Lind, L, Pollare, T, Berne, C, Lithell, H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128, 1177 1183. 88 Neutel, JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101, 71S 82S. 89 O'byrne, S & Feely, J. Effects of drugs on glucose tolerance in non-insulin-dependent diabetics (Part I). Drugs 1990; 40, 6 18. 90 Veterans Administration Cooperative Study Group on Antihypertensive Agents. Hypertension: propranolol or hydrochlorothiazide alone for the initial treatment of hypertension. IV. Effect on plasma glucose and glucose tolerance. 1985; 7, 1008 1016. 91 Ames, RP & Hill, P. Improvement of glucose tolerance and lowering of glycohemoglobin and serum lipid concentrations after discontinuation of antihypertensive drug therapy. Circulation 1982; 65, 899 904. 92 Ramsay, LE, Yeo, WW, Jackson, PR. Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients. J Cardiovasc Pharmacol 1992; 20 (Suppl.), S49 S53. 93 Pollare, T, Lithell, H, Morlin, C, Prantare, H, Hvarfner, A, Ljunghall, S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7, 551 559. 94 Pollare, T, Lithell, H, Selinus, I, Berne, C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31, 415 420. 95 Waagstein, F, Bristow, MR, Swedberg, K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342, 1441 1446. 96 Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997; 349, 375 380. 97 Packer, M, Bristow, MR, Cohn, JN et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334, 1349 1355. 98 The Cardiac Insufficiency Bisoprolol Study, II. (CIBIS-II): a randomised trial. Lancet 1999; 353, 9 13. 99 Helgeland, A, Leren, P, Foss, OP, Hjermann, I, Holme, I, Lund-Larsen, PG. Serum glucose levels during long-term observation of treated and untreated men with mild hypertension: The Oslo study. Am J Med 1984; 76, 802 805. 100 Lager, I, Attvall, S, Eriksson, BM, Von Schenk, H, Smith, U. Studies on the insulin-antagonistic effect of catecholamines in normal man: evidence for the importance of beta 2-receptors. Diabetologia 1986; 29, 409 416. 101 Smith, RS & Warren, DJ. Effect of acute oral beta adrenergic blockade on muscle blood flow in man. Cardiovasc Res 1982; 16, 205 208. 102 DeFronzo, RA, Thorin, D, Felber, JP et al. Effect of beta and alpha adrenergic blockade on glucose-induced thermogenesis in man. J Clin Invest 1984; 73, 633 639. 103 Mauras, N, Blizzard, RM, Thorner, MO, Rogol, AD. Selective beta 1-adrenergic receptor-blockade with atenolol enhances growth hormone releasing hormone and mediated growth hormone release in man. Metabolism 1987; 36, 369 372. 104 Rössner, S, Taylor, CL, Byington, RP, Furberg, CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ 1990; 300, 902 903. 105 Heinemann, L, Heise, T, Ampudia, J et al. Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest 1995; 25, 595 600. 106 William-Olsson, T, Fellenius, E, Bjorntorp, P, Smith, U. Differences in metabolic responses to beta-adrenergic stimulation after propranolol or metoprolol administration. Acta Med Scand 1979; 205, 201 206. 107 Ekberg, G & Hansson, BG. Glucose tolerance and insulin release in hypertensive patients treated with the cardioselective beta-receptor blocking agent metoprolol. Acta Med Scand 1977; 202, 393 397. 108 Fagerberg, B, Berglund, A, Holme, E, Wilhelmsen, L, Elmfeldt, D. Metabolic effects of controlled-release metoprolol in hypertensive men with impaired or diabetic glucose tolerance: a comparison with atenolol. J Intern Med 1990; 227, 37 43. 109 Pollare, T, Lithell, H, Selinus, I, Berne, C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298, 1152 1157. 110 Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997; 18, 736 753. 111 Greenwald, L & Becker, RC. Expanding the paradigm of the renin-angiotensin system and angiotensin-converting enzyme inhibitors. Am Heart J 1994; 128, 997 1009. 112 Donnelly, R. Angiotensin-converting enzyme inhibitors and insulin sensitivity: metabolic effects in hypertension, diabetes, and heart failure. J Cardiovasc Pharmacol 1992; 20 (Suppl.), S38 S44. 113 Vuorinen-Markkola, H & Yki-Jarvinen, H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995; 44, 85 89. 114 Paolisso, G, Balbi, V, Gambardella, A et al. Lisinopril administration improves insulin action in aged patients with hypertension. J Hum Hypertens 1995; 9, 541 546. 115 Bohlen, L, Bienz, R, Doser, M et al. Metabolic neutrality of perindopril: focus on insulin sensitivity in overweight patients with essential hypertension. J Cardiovasc Pharmacol 1996; 27, 770 677. 116 Wiggam, MI, Hunter, SJ, Atkinson, AB et al. Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens 1998; 16, 1651 7165. 117 Lerch, M, Weidmann, P, Ho, MP et al. Metabolic effects of temocapril in hypertensive patients with diabetes mellitus type 2. J Cardiovasc Pharmacol 1999; 33, 527 335. 118 Carvalho, CR, Thirone, AC, Gontijo, JA, Velloso, LA, Saad, MJ. Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 1997; 46, 1950 7195. 119 Higashiura, K, Ura, N, Miyazaki, Y, Shimamoto, K. Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. J Hum Hypertens 1999; 13 (Suppl.), S71 S74. Citing Literature Volume2, Issue4July 2000Pages 203-212 ReferencesRelatedInformation